Integrating public policy and public affairs in a pharmaceutical marketing program: The AIDS pandemic

Journal of Public Policy and Marketing

Volumn 23, Issue 2, 2004, Pages 128-139

  Kennedy, Charles R ^a   Harris, Frederick H De B ^b   Lord, Michael ^a,c  

^a Flow Inst for International Studies

^b Department of Economics ^*

^c WAKE FOREST UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 11144290980     PISSN: 07439156     EISSN: 15477207     Source Type: Journal    
DOI: 10.1509/jppm.23.2.128.51404     Document Type: Review

References (38)

1. Attaran, Amir (2003), Comments made in a panel discussion, The Pfizer Journal, 4 (1), 1-37.
2. _ and Lee Gillespie-White (2001), "Do Patents for Antiretroviral Drugs Constrain Access to AIDS Treatment in Africa?" Journal of the American Medical Association, 286 (October 17), 1886-92.
3. Bain & Company (2003), "Rebuilding Big Pharma's Business Model," (accessed December 2003), [available at http://www. bain.com/bainweb/Publications].
4. BusinessWeek (2003), "Big Pharma Needs a New Prescription for Growth," (June 30), 40.
5. Carter, Terry (2002), "Drug Wars," ABA Journal, 88 (December), 40-45.
6. Challener, Cynthia (2003), "Finding the Bright Spots in the Vanishing Pharma Pipeline," Chemical Market Reporter, 263 (2), 4.
7. Collins, Tracy (2002), "The Pharmaceutical Companies vs. AIDS Victims: A Classic Case of Bad vs. Good? A Look at the Struggle Between International Intellectual Property Rights and Access to Treatment," Syracuse Journal of International Law and Commerce, 29 (159), 159-83.
8. Danzon, P.M. (1997), "Price Discrimination for Pharmaceuticals: Welfare Effects in the U.S. and the EU," International Journal of the Economics of Business, 4 (3), 301-321.
9. Ford, Nathan and Ellen t'Hoen (2001), "The Global Health Fund: Moral Imperative or Industry Subsidy," The Lancet, 358 (August 18), 578.
10. Freeman, Edward R. (1984), Strategic Management: A Stakeholder Approach. Boston: Pitman Publishing.
11. Glaxo Welcome (2000), "HIV in Developing Countries," research report, (October 5).
12. Global Fund (2003), "Annual Report 2002/2003," (accessed November 2003), [available at http://www.theglobalfund.org].
13. Kaptein, Muel and Rob Van Tulder (2003), "Toward Effective Stakeholder Dialogue," Business and Society Review, 108 (2), 203-224.
14. Kremer, Michael (2000), "Creating Markets for New Vaccines," in Innovation Policy and the Economy, Adam B. Jaffe, John Lerner, and Scott Stern, eds. Cambridge, MA: The MIT Press, 35-118.
15. _ (2002), "Pharmaceuticals and the Developing World," Journal of Economic Perspective, 16 (4), 67-90.
16. Medecins Sans Frontieres (2003a), (accessed November 2003), [available at http://www.doctorswithoutborders.org].
17. Medecins Sans Frontieres, Doctors Without Borders (2003b), "Flawed WTO Drugs Deal... Developing Countries," (accessed November 2003), [available at http://www. doctorswithoutborders.org/pr].
18. Moran, Mary and Nathan Ford (2003), "The G8 and Access to Medicines: No More Broken Promises," The Lancet, 361 (May 10), 1578.
19. National Intelligence Council (2000) "The Global Infectious Disease Threat and Its Implications for the United States," (accessed November 2003), [available at http://www.odci.gov/ nic/pubs].
20. _ (2002), "The Next Wave of HIV/AIDS: Nigeria, Ethiopia, Russia, India and China," (accessed November 2003), [available at http://www.odci.gov/nic/pubs].
21. The New York Times (2003a), "Gates Aims Billions to Attach World's Neediest," (July 13), A1.
22. _ (2003b), "W.H.O. Aims to Treat 3 Million for AIDS," (December 1), A6.
23. Oxfam (2003), "Flawed WTO Drugs Deal Will Do Little to Secure Future Access to Medicines in Developing Countries," (accessed August 30), [available at http://www.oxfam.org].
24. Paul, James A. (2001), "Non-Governmental Organizations," in The Oxford Companion to Politics of the World, Joel Krieger, ed. Oxford: Oxford University Press, 598-601.
25. Pharma Market Letter (2002), "Ernst & Young's First Ever Global Pharma Report Highlights Key Issues for the Future," (December 23), [available at http://www.lexis-nexis.com].
26. Reinhardt, Uwe R. (2001), "Perspectives on the Pharmaceutical Industry," Health Affairs, 20 (September/October), 136-49.
27. Reisel, William and Linda Sama (2003), "The Distribution of LifeSaving Pharmaceuticals: Viewing the Conflict Between Social Efficiency-Economic Efficiency Through a Social Contact Lens," Business and Society Review, 108 (3), 365-87.
28. Rosen, Sidney, Jeffrey R. Vincent, William MacLeod, Matthew Fox, and Donald M. Thea (2003), "AIDS Is Your Business," Harvard Business Review, (February), 81-87.
29. Tenet, George (2003), "The Worldwide Threat in 2003: Evolving Dangers in a Complex World," (accessed February 11), [available at http://www.odci.gov/cia/pubaffairs/speeches/dci].
30. UNAIDS (2003a) "A Joint Response to HIV/AIDS," (accessed November 2003), [available at http://www.unaids.org].
31. _ (2003b) "The Declaration of Commitment on HIV/AIDS," press release, (accessed September 22), [available at http:// www.unaids.org].
32. _ (2003c) "Africa AIDS Fight Remains Only Half Funded," press release, (accessed September 21), [available at http:// www.unaids.org].
33. Vogel, Ronald J. (2003), Comments made in a panel discussion, The Pfizer Journal, 4 (1), 1-37.
34. Washington Post (2003), "Politics Slows Agreement on Lifesaving Drugs," (July 4), El.
35. Watson, Rory (2002), "EU Clamps Down on Reimportation of Cheap Drugs Meant for Africa," British Medical Journal, 325 (November 9), 1058.
36. WHO (2003), "WHO-UNAIDS HIV Vaccine Initiative," (accessed November 2003), [available at http://www.who.int/ vaccine_research/diseases/hiv/en].
37. World Business Council for Sustainable Development (2002), Stakeholder Dialogue: The WBCD's Approach to Engagement. Switzerland: World Business Council for Sustainable Development.
38. WTO (2003),"Decision Removes Final Patent Obstacle to Cheap Drug Imports," (accessed August 30), [available at http://www. wto.org].